Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age

Abstract

Osteogenesis imperfecta (OI) is an inherited disorder characterized by bone fragility and low bone mass. Low bone density and fracture is a cause of morbidity. Limited data exists on bisphosphonate treatment in patients under 24 months of age. The objective of the study was to examine the safety and efficacy of pamidronate in children under 24 months with… (More)
DOI: 10.1007/s00774-014-0618-2

Topics

2 Figures and Tables

Cite this paper

@article{Kusumi2014BeneficialEO, title={Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age}, author={Kirsten Kusumi and Rose Mary Ayoob and Sasigarn A. Bowden and Susan Ingraham and John D. Mahan}, journal={Journal of Bone and Mineral Metabolism}, year={2014}, volume={33}, pages={560-568} }